Kumar Shria, Chandrasekhara Vinay, Kochman Michael L, Ahmad Nuzhat, Attalla Sara, Ho Immanuel K, Jaffe David L, Lee Peter J, Panganamamula Kashyap V, Saumoy Monica, Fortuna Danielle, Ginsberg Gregory G
Division of Gastroenterology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Dis Esophagus. 2020 Aug 3;33(8). doi: 10.1093/dote/doaa027.
Given their malignant potential, resection of esophageal granular cell tumors (GCTs) is often undertaken, yet the optimal technique is unknown. We present a large series of dedicated endoscopic resection using band ligation (EMR-B) of esophageal GCTs. Patients diagnosed with esophageal GCTs between 2002 and 2019 were identified using a prospectively collected pathology database. Endoscopic reports were reviewed, and patients who underwent dedicated EMR-B of esophageal GCTs were included. Medical records were queried for demographics, findings, adverse events, and follow-up. We identified 21 patients who underwent dedicated EMR-B for previously identified esophageal GCT. Median age was 39 years; 16 (76%) were female. Eight (38%) had preceding signs or symptoms, potentially attributable to the GCT. Upon endoscopic evaluation, 12 (57%) were found in the distal esophagus. Endoscopic ultrasound was used in 15 cases (71%). Median lesion size was 7 mm, interquartile range 4 mm-8 mm. The largest lesion was 12 mm. A total of 20 (95%) had en bloc resection confirmed with pathologic examination. The only patient with tumor extending to the resection margin underwent surveillance endoscopy that showed no residual tumor. No patients experienced bleeding, perforation, or stricturing in our series. No patients have had known recurrence of their esophageal GCT. EMR-B of esophageal GCT achieves complete histopathologic resection with minimal adverse events. EMR-B is safe and effective and seems prudent compared with observation for what could be an aggressive and malignant tumor. EMR-B should be considered first-line therapy when resecting esophageal GCT up to 12 mm in diameter.
鉴于食管颗粒细胞瘤(GCTs)具有恶性潜能,通常会对其进行切除,但最佳技术尚不清楚。我们展示了一系列使用带结扎术的内镜下食管GCTs切除术(EMR-B)。利用前瞻性收集的病理数据库,确定了2002年至2019年间被诊断为食管GCTs的患者。回顾了内镜报告,纳入了接受过食管GCTs专用EMR-B的患者。查询病历以获取人口统计学信息、检查结果、不良事件和随访情况。我们确定了21例接受过专用EMR-B治疗的先前确诊的食管GCT患者。中位年龄为39岁;16例(76%)为女性。8例(38%)有先前的体征或症状,可能归因于GCT。在内镜评估中,12例(57%)位于食管远端。15例(71%)使用了内镜超声。中位病变大小为7mm,四分位间距为4mm - 8mm。最大病变为12mm。共有20例(95%)经病理检查证实为整块切除。唯一肿瘤延伸至切除边缘的患者接受了监测内镜检查,结果显示无残留肿瘤。在我们的系列研究中,没有患者发生出血、穿孔或狭窄。没有患者出现食管GCT复发。食管GCT的EMR-B可实现完整的组织病理学切除,不良事件最少。EMR-B安全有效,与对可能具有侵袭性和恶性的肿瘤进行观察相比,似乎更为谨慎。在切除直径达12mm的食管GCT时,EMR-B应被视为一线治疗方法。